glp 1 meds oral glp-1 drugs Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients Rewriting the Patient Journey: GLP‑1

Message with your care team and schedule follow-ups

In addition, Igarashi et al

Suitable candidates typically include adults with a Body Mass Index (BMI) of 30 kg/m or higher, indicating obesity, or those with a BMI of at least 27 kg/m and weight-related health conditions, such as elevated cholesterol levels, hypertension, or type 2 diabetes

Taken together, the metabolic modifications associated with GLP-1RA treatment appear to have a favorable impact on CV systems, such as vascular function [19, 20], subsequently leading to anti-atherosclerotic effects in T2D patients

Improved energy and daytime alertness: Follows the sleep improvement as quality rest compounds over the 10-day window